ArticleGigaScience2025
SynProtX: a large-scale proteomics-based deep learning model for predicting synergistic anticancer drug combinations.
Article in GigaScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Deep Learning-Enabled Multi-Omics Integration: A New Frontier in Precise Drug Target Discovery.Biology · 2026Review
- Applying biotechnology to overcome cancer drug resistance and improve public health outcomes.Osong public health and research perspectives · 2026Article
- SynProtX: a large-scale proteomics-based deep learning model for predicting synergistic anticancer drug combinations.GigaScience · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
motivationDrug combination therapy plays a pivotal role in addressing the molecular heterogeneity of cancer, improving treatment efficacy, minimizing resistance, and reducing toxicity. Deep learning approaches have significantly advanced drug combination discovery by addressing the limitations of conventional laboratory experiments, which are time-consuming and costly. While most existing models rely on the molecular structure of drugs and gene expression data, incorporating protein-level expression provides a more accurate representation of cellular behavior and drug responses. In this study, we introduce SynProtX, an enhanced deep learning model that explicitly integrates large-scale proteomics with deep neural networks (DNNs) and the molecular structure of drugs with graph neural networks (GNNs).
resultsThe SynProtX-GATFP model, which combines molecular graphs and fingerprints through a graph attention network architecture, demonstrated superior predictive performance for the FRIEDMAN study dataset. We further evaluated its cell line-specific performance, which achieved accuracy across diverse tissue and study datasets. By incorporating protein expression data, the model consistently enhanced predictive performance over gene expression-only models, reflecting the functional state of cancer cells. The generalizability of SynProtX was rigorously validated using cold-start prediction, including leave-drug-combination-out, leave-drug-out, and leave-cell-line-out validation strategies, highlighting its robust performance and potential for clinical applicability. Additionally, SynProtX identified key cancer-associated proteins and molecular substructures, offering novel insights into the biological mechanisms underlying drug synergy. These findings highlight the potential of integrating large-scale proteomics and multiomics data to advance anticancer drug design and combination therapy strategies for personalized medicine. Availability and implementation: https://github.com/manbaritone/SynProtX.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.